WASHINGTON (Reuters) - The U.S. Supreme Court on Monday brought to an end Bristol-Myers Squibb Co's attempt to revive patent protection for its Baraclude treatment for hepatitis B.
The high court declined to hear Bristol-Myers' challenge to an appeals court ruling in favor of generic rival Teva Pharmaceutical Industries Ltd, which had successfully challenged the patent.
00:59 Federal judge tosses out life sentences for DC sniper Malvo21
18:43 Another appeals court rules against President Trump's travel banÂ12
18:19 Federal appeals court largely maintains freeze of Trump’s travel ban19
18:07 Trump's Travel Ban Remains Frozen After Appeals Court Ruling19